WebNov 4, 2015 · Here we describe the synthesis and biological properties of two types of star-shaped polymer-doxorubicin conjugates: non-targeted conjugate prepared as long-circulating high-molecular-weight (HMW) polymer prodrugs with a dendrimer core and a targeted conjugate with the anti-CD20 monoclonal antibody (mAb) rituximab (RTX). The … WebApr 5, 2024 · At Stage 1, three treatment arms, Flebogamma® 5% DIF 2 g/kg of body weight (IVIG 2 g/kg arm), or the equivalent volume of Normal Saline Solution (40 ml/kg of body weight), or Flebogamma® 5% DIF 1 g/kg of body weight plus the equivalent volume of Normal Saline Solution (20 ml/kg of body weight) (IVIG 1 g/kg arm) will be administered …
A multicenter, prospective, open label, historically controlled ...
WebDec 5, 2024 · The recommended initial infusion rate of Flebogamma 10% DIF is 0.01 mL per kg body weight per minute (1 mg per kg per min) for the first thirty minutes. If tolerated, the rate may be gradually increased to 0.04 mL per kg body weight per minute (4 mg per kg per min) and if tolerated, gradually increased to a maximum of 0.08 mL per kg body … WebSummary of Product Characteristics and Product Information by Country. chateau b de brehat
FLEBOGAMMA® 10% DIF Intravenous Immunoglobulin
WebFeb 3, 2024 · Single dose toxicity studies were carried out in rats and mice. The absence of mortality in the non-clinical studies performed with Flebogamma DIF with doses up to 2500 mg/kg, and the lack of any confirmed relevant adverse sign affecting respiratory, circulatory and central nervous system of the treated animals support the safety of Flebogamma DIF. WebJun 27, 2014 · Flebogamma 5% DIF 1 g/kg of body weight administered via intravenous infusion on Day 1 and 20 mL/kg of body weight of normal saline solution (equivalent volume of 1 g/kg of body weight Flebogamma® 5% DIF infusions) will also be administered on a separate day, for a total dosing period of 2 consecutive days. every 4 weeks for 52 weeks. WebOct 21, 2024 · The IVIg group received IVIg (human) flebogamma 5% DIF GRIFOLS, in addition to their prior initial treatment (the initial treatment methods continued in the treatment group during the trial). Treatment group patients received four vials of 5 gm5 IVIg daily for three consecutive days. Those patients who died before 72 h after the … customer care advisor boots